Thyroid hormone treatment intensity linked to increased risk of cardiovascular mortality

The findings highlight the importance of regular monitoring of thyroid function and prompt correction of over- and under-treatment with thyroid hormone to reduce patient harm.

11:02 AM

Author | Jordyn Imhoff

heart image lab note navy blue yellow
Michigan Medicine

One synthetic thyroid hormone, levothyroxine, lands itself on the United State's list of top three prescribed medications in the country over the last decade. Simultaneously, despite all efforts to reduce its prevalence, heart disease remains the leading cause of death in Americans, affecting nearly half of the population aged 20 years and older.

However, studies evaluating the association between the intensity of thyroid hormone treatment and heart disease-related death are scarce, according to University of Michigan Health endocrinologist and U-M Institute for Healthcare Policy and Innovation member Maria Papaleontiou, M.D.

In a study published in JAMA Network Open, Papaleontiou sought to evaluate the relationship between thyroid hormone treatment intensity and cardiovascular mortality in a retrospective cohort study of more than 705,000 U.S. veterans who received thyroid hormone therapy between 2004 and 2017.

The work from Papaleontiou's team follows an observation that up to half of patients who receive thyroid hormone therapy have exogenous hyperthyroidism or hypothyroidism, which is having thyrotropin levels inappropriately below or above the normal range, respectively. Could the amount of thyrotropin abnormality outside the normal range be associated with increased risk of cardiovascular death?

Like Podcasts? Add the Michigan Medicine News Break on Spotify, Apple Podcasts or anywhere you listen to podcasts.

"We found that, after adjusting for age, sex, race/ethnicity, and traditional cardiovascular risk factors like hypertension, smoking and previous heart disease, this subset of patients did have an increased risk for cardiovascular mortality compared to those with euthyroidism, or normal thyroid function," said Papaleontiou.

Live your healthiest life: Get tips from top experts weekly. Subscribe to the Michigan Health blog newsletter

The findings suggest that the intensity of thyroid hormone treatment could be a modifiable risk factor for cardiovascular mortality, and that thyrotropin levels lower than 0.1 mIU/L and higher than 20 mIU/L are of particular concern for this outcome.

Notably, the study results found those in older age categories are a vulnerable population for these adverse health outcomes and should be targeted for interventions to avoid over- and under-treatment with thyroid hormone.

Patients with a history of thyroid cancer were excluded from the study because lower thyrotropin levels are often targeted in these patients to reduce the risk of cancer recurrence. Additionally, patients prescribed lithium or amiodarone were excluded because of the medications' association with abnormal thyroid function results.

"These findings emphasize the importance of maintaining euthyroidism to decrease cardiovascular risk and death among patients receiving thyroid hormone treatment, which necessitates regular monitoring of thyroid function and correction of both over-treatment and under-treatment with thyroid hormones to reduce patient harm," said Papaleontiou.

Headlines from the frontlines: The power of scientific discovery harnessed and delivered to your inbox every week. Subscribe to the Michigan Health Lab blog newsletter

Additional authors include Josh M. Evron, M.D., from the University of North Carolina, Chapel Hill, Scott L. Hummel, M.D., M.S., David Reyes-Gastelum, M.S., and Megan R. Haymart, M.D., all from University of Michigan Health, and Mousumi Banerjee, Ph.D., from University of Michigan School of Public Health.

This work was supported by the National Institute on Aging of the National Institutes of Health under award K08 AG049684 and by a pilot grant co-funded by the Claude D. Pepper Older Americans Independence Center, the Michigan Institute for Clinical and Health Research, and the Michigan Biology of Cardiovascular Aging. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Paper cited: "Association of Thyroid Hormone Treatment Intensity with Cardiovascular Mortality Among US Veterans," JAMA Network Open. DOI: 10.1001/jamanetworkopen.2022.1186


More Articles About:

Lab Notes Basic Science and Laboratory Research Heart disease Heart Failure Preventive Cardiology Thyroid Diseases Soldiers and War veterans All Research Topics
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Mother sits on a couch with a laptop on her lap while an elementary school age boy sits next to her playing on a tablet device.
Health Lab

New questionnaire aims to improve understanding of demand avoidance in children, teens

Pathological demand avoidance is a pattern of intense distress and avoidance of demands in children. A new questionnaire from University of Michigan researchers creates a structured way to assess these behaviors.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
A smartphone displaying a red heart with a white EKG line on its screen, set against a teal background.
Health Lab

Mobile health app improves heart failure medication use, dosing after hospitalization

A U-M-led trial found a mobile app improved use and dosing of recommended heart failure medications during the 90 days following a hospital discharge.
Boy in white t-shirt, just chin showing, with hands holding a stethoscope on his chest.
Health Lab

Distance, insurance, social factors may hinder access to lifesaving heart monitoring for children

New research suggests that social, economic and geographic factors may influence whether patients who undergo the Fontan surgery for complex congenital heart disease receive the recommended lifelong cardiac monitoring.